- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Echinocandin b.
Displaying page 1 of 1.
EudraCT Number: 2004-002944-90 | Sponsor Protocol Number: EORTC 65041 | Start Date*: 2005-07-26 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: A Multicenter, Open, Phase II Study to Estimate the activity and safety of Caspofungin (CASP) in the First-line Treatment of probable and proven Invasive Aspergillosis 'IA) in Patients with Hematol... | |||||||||||||
Medical condition: Invasive aspergillosis in patients with haematological malignancies (HM)/autologous Hematopoietic Stem Cell Transplantation (HSCT) – group A- and patients with allogeneic HSCT transplantation – gro... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) IT (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001585-15 | Sponsor Protocol Number: 2018-01671 | Start Date*: 2020-01-30 |
Sponsor Name:Centre Hospitalier Universitaire Vaudois | ||
Full Title: PTX3 genetically stratified randomized double-blinded allocation eventdriven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia | ||
Medical condition: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome in transformation (MDSit) who receive antifungal profylaxis during their treatment with an intensive chemotherapy regimen, inc... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018695-25 | Sponsor Protocol Number: Anidulafungine/péritonite | Start Date*: 2010-05-08 | |||||||||||
Sponsor Name:ADRFARCP | |||||||||||||
Full Title: Etude prospective de la prescripion d'anidulafungine pour infections intra-abdominales graves hospitalisées en réanimation | |||||||||||||
Medical condition: patients hospitalisés en unité de réanimation pour infection intra-abdominale grave à levures | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005278-11 | Sponsor Protocol Number: A8851022 | Start Date*: 2009-03-06 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN PATIENTS WITH CANDIDA DEEP TISSUE INFECTION | |||||||||||||
Medical condition: INVASIVE CANDIDIA INFECTIONS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Prematurely Ended) BE (Prematurely Ended) IE (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005277-35 | Sponsor Protocol Number: A8851021 | Start Date*: 2009-02-26 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN NEUTROPENIC PATIENTSWITH INVASIVE CANDIDA INFECTION | |||||||||||||
Medical condition: INVASIVE CANDIDIA INFECTIONS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) IE (Prematurely Ended) SK (Prematurely Ended) FR (Completed) IT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007973-19 | Sponsor Protocol Number: VORI-ZonMW | Start Date*: 2009-04-09 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Pharmacologic optimization of voriconazole - a prospective clustered group-randomized cross-over trial of therapeutic drug monitoring | ||
Medical condition: The objective of this prospective stratified cluster randomized cross-over trial is to determine whether pharmacologic optimization of voriconazole by means of therapeutic drug monitoring (TDM) res... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001433-74 | Sponsor Protocol Number: LOCAL/2017/CR-01 | Start Date*: 2017-06-29 | |||||||||||
Sponsor Name:CHU de NIMES | |||||||||||||
Full Title: Screening Anti-Fungal Exposure in Intensive Care Units – The French Cohort | |||||||||||||
Medical condition: The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004150-32 | Sponsor Protocol Number: A8851008 | Start Date*: 2008-11-18 | |||||||||||
Sponsor Name:Pfizer, Spain | |||||||||||||
Full Title: ESTUDIO PROSPECTIVO ABIERTO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE LA ANIDULAFUNGINA EN EL TRATAMIENTO DE NIÑOS Y ADOLESCENTES CON CANDIDIASIS INVASIVA, INCLUIDA LA CANDIDEM... | |||||||||||||
Medical condition: CANDIDIASIS INVASIVA, INCLUIDA CANDIDEMIA | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) FR (Completed) PT (Completed) IT (Completed) GR (Completed) Outside EU/EEA GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021231-14 | Sponsor Protocol Number: A1501095 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE SAFETY, TOLERABILITY, AND EFFICACY OF VORICONAZOLE AND ANIDULAFUNGIN IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF INVA... | |||||||||||||
Medical condition: Primary therapy of invasive aspergillosis (IA) in pediatric subjects aged 2 to 17 years. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) FR (Ongoing) NL (Ongoing) DK (Prematurely Ended) PL (Completed) DE (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
